ProfileGDS5678 / 1418381_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 76% 76% 77% 79% 77% 77% 70% 74% 76% 80% 77% 77% 74% 78% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.030976
GSM967853U87-EV human glioblastoma xenograft - Control 25.0990276
GSM967854U87-EV human glioblastoma xenograft - Control 35.2441677
GSM967855U87-EV human glioblastoma xenograft - Control 45.5958879
GSM967856U87-EV human glioblastoma xenograft - Control 55.2040677
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.066377
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.3774970
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.7645774
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.0674176
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.6529180
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.1712977
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.3140877
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.8662274
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.3702578